Zhejiang Shapuaisi Pharmaceutical (603168.SH) will distribute a dividend of 0.021 yuan per share for the year 2023, with a record date of June 12th.
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company will implement the annual equity distribution for 2023, distributing... per share.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): The production capacity of the P2 and P3 production lines is currently about 300 million units.
On June 4th, Gelunhui reported that zhejiang shapuaisi pharmaceutical (603168.SH) stated in its 2023 annual and Q1 2024 performance briefing that the single-dose eyedrop workshop P2 and P3 production lines could produce normal products after passing compliance checks in January 2024. The P2 and P3 production lines currently have a production capacity of about 300 million units.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): Currently actively promoting the research and development of tropicamide hydrochloride eye drops projects.
On June 4th, Gelon Hui reported that Zhejiang Shapuaisi Pharmaceutical (603168.SH) stated during the company's 2023 and 2024 Q1 performance briefing that they are actively promoting the research and development of Tropicamide hydrochloride eye drops project.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): Atropine sulfate eye drops have entered phase III clinical trial.
At the 2023 and Q1 2024 performance briefing, Zhejiang Shapuaisi Pharmaceutical (603168.SH) stated that it is actively promoting the research and development of projects such as atropine sulfate eye drops and scopolamine hydrobromide eye drops. Among them, atropine sulfate eye drops have entered Phase III clinical trials. New drug research and development is a long cycle, high investment, and high-risk work, and there are technical risks and policy changes risks in the R&D process. At the same time, the market promotion of pharmaceuticals will also be affected by uncertainties such as industry, market environment, and competition. We sincerely request the investment community's attention.
Sharp Ash (603168.SH): Shanghai Jingxing plans to reduce its holdings by no more than 1%
Glonghui, May 7, 丨 ShapeAce (603168.SH) announced that due to the needs of its own strategic development plan and capital requirements for foreign investment, Shanghai Jingxing will make appropriate holdings reduction arrangements according to market conditions within 3 months after the announcement of the current holdings reduction plan, that is, from May 14, 2024 to August 11, 2024; it is proposed to reduce its holdings through centralized bidding transactions through the Shanghai Stock Exchange system, with no more than 3.79 million shares, that is, no more than 1% of Sharp Ace's total share capital.
Sharp Ash (603168.SH): Net profit of 4.296,600 yuan in the first quarter decreased by 80.93% year-on-year
On April 29, GLONGHUI (603168.SH) released its first quarter report. Operating revenue was 138 million yuan, down 15.02% year on year, net profit of 4.296,600 yuan, down 80.93% year on year, after deducting non-net profit of 4.359 million yuan, down 82.06% year on year, with basic earnings of 0.01 yuan per share.
Investors Can Find Comfort In Zhejiang Shapuaisi PharmaceuticalLtd's (SHSE:603168) Earnings Quality
Shareholders appeared unconcerned with Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) lackluster earnings report last week. We think that the softer headline numbers might be getting coun
Sharp Ash (603168.SH) received approval notice for sodium acetate ringer injection drug supplement application
Sharp Ice (603168.SH) issued an announcement. The company received the approval and issuance of sodium acetate by the State Drug Administration...
Sharp Ash (603168.SH) announced its 2023 annual results, net profit of 25.41 million yuan, a year-on-year decrease of 43.23%
Zhitong Finance App News, according to the 2023 Annual Report. The company achieved revenue of 645 million yuan in 2023, an increase of 17.37% over the previous year; net profit to mother of 25.41 million yuan, a year-on-year decrease of 43.23%; after deducting loss of 4.01 million yuan in non-net profit, which changed from profit to loss over the previous year; basic earnings per share were 0.07 yuan. 603168.SH The company plans to pay a cash dividend of 0.21 yuan (tax included) for every 10 shares. During the reporting period, the company achieved operating income of 644.9702 million yuan, an increase of 954.3332 million yuan over the same period last year, an increase of 17.37% over the same period last year, mainly
Shapuaisi Pharma Gets China's Nod to Market Sodium Hyaluronate Eye Drops
Zhejiang Shapuaisi Pharmaceutical (SHA:603168) obtained marketing approval from China's medical products administrator for its sodium hyaluronate eye drops, according to a Wednesday filing with the Sh
Sharp Ace (603168.SH): Obtained the “Drug Registration Certificate” for sodium hyaluronate eye drops
On April 16, Gelonghui (603168.SH) announced that the company received the “Drug Registration Certificate” for sodium hyaluronate eye drops approved and issued by the State Drug Administration. The sodium hyaluronate eye drops approved this time are single-dose products. The indications are: corneal epithelial damage accompanied by the following diseases: endogenous diseases such as Sjögren's syndrome (Sjögren's syndrome), Stevens-Johnson syndrome (Stevens-Johnson syndrome), dry eye syndrome (dry eye syndrome); after surgery, medicine
Shapuaisi Pharma Gets Marketing Authorization for Moxifloxacin Hydrochloride Eye Drops
Zhejiang Shapuaisi Pharmaceutical (SHA:603168) received approval from China's National Medical Products Administration to have the marketing authorization for moxifloxacin hydrochloride eye drops, acc
Some Confidence Is Lacking In Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) P/E
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) as a stock to potentially avoi
ShapeAce (603168.SH): Fluconazole sodium chloride injection passed the consistent evaluation of generic drug quality and efficacy
Zhitong Finance App News, ShapeAce (603168.SH) issued an announcement. Recently, the company received the “Drug Supplement Application Approval Notice” for fluconazole sodium chloride injection approved and issued by the State Drug Administration. After review, the drug passed the consistent evaluation of generic drug quality and efficacy. The company's fluconazole sodium chloride injection has passed the consistent evaluation of the quality and efficacy of generic drugs, which is conducive to improving the market competitiveness of this product, expanding the market sales of the product, and having a positive impact on the company's business performance.
ShapeAce (603168.SH) received approval notice for Moxifloxacin hydrochloride eye drops drug supplement application
Sharp Ash (603168.SH) issued an announcement. Recently, the company received approval from the State Drug Administration...
Shapex (603168.SH): Cefixime dispersible tablets are considered to have passed the generic drug consistency evaluation
Sharp Ash (603168.SH) issued an announcement. Recently, the company received approval from the State Drug Administration...
Are Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
With its stock down 34% over the past month, it is easy to disregard Zhejiang Shapuaisi PharmaceuticalLtd (SHSE:603168). However, the company's fundamentals look pretty decent, and long-term financi
Here's Why Zhejiang Shapuaisi PharmaceuticalLtd (SHSE:603168) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But the reality is that when a company lose
ShapeAce (603168.SH): Products Pazufloxacin Mesylate Eye Drops and Levofloxacin Eye Drops Can Be Used to Treat Red Eye Disease
Gelonghui, January 15 | ShapeAce (603168.SH) said on the investor interactive platform that the company's products pazufloxacin mesylate eye drops and levofloxacin eye drops can be used to treat red eye disease.
Sharp Ace (603168.SH): Currently no business dealings with Huawei Hongmeng
GLONGHUI January 15 丨 ShapeAce (603168.SH) said on the investor interactive platform that the company currently has no business dealings with Huawei Hongmeng.
No Data